CELZ
Price
$4.51
Change
-$0.03 (-0.66%)
Updated
Dec 1, 6:59 PM EST
CYTO
Price
$0.32
Change
-$0.07 (-17.95%)
Updated
Dec 1, 6:59 PM EST
Ad is loading...

Compare trend and price CELZ vs CYTO

Header iconCELZ vs CYTO Comparison
Open Charts CELZ vs CYTOBanner chart's image
Creative Medical Technology Holdings
Price$4.51
Change-$0.03 (-0.66%)
Volume$700
CapitalizationN/A
Altamira Therapeutics
Price$0.32
Change-$0.07 (-17.95%)
Volume$5.45M
CapitalizationN/A
View a ticker or compare two or three
CELZ vs CYTO Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
CELZ vs. CYTO commentary
Dec 03, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a StrongBuy and CYTO is a StrongSell.

COMPARISON
Comparison
Dec 03, 2023
Stock price -- (CELZ: $4.57 vs. CYTO: $0.31)
Brand notoriety: CELZ and CYTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELZ: 21% vs. CYTO: 73%
Market capitalization -- CELZ: $5.89M vs. CYTO: $1.76M
CELZ [@Biotechnology] is valued at $5.89M. CYTO’s [@Biotechnology] market capitalization is $1.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELZ’s FA Score shows that 0 FA rating(s) are green whileCYTO’s FA Score has 1 green FA rating(s).

  • CELZ’s FA Score: 0 green, 5 red.
  • CYTO’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTO is a better buy in the long-term than CELZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELZ’s TA Score shows that 5 TA indicator(s) are bullish while CYTO’s TA Score has 6 bullish TA indicator(s).

  • CELZ’s TA Score: 5 bullish, 3 bearish.
  • CYTO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CELZ and CYTO are a good buy in the short-term.

Price Growth

CELZ (@Biotechnology) experienced а -2.56% price change this week, while CYTO (@Biotechnology) price change was +11.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +30.64%, and the average quarterly price growth was +27.15%.

Reported Earning Dates

CELZ is expected to report earnings on Aug 30, 2023.

CYTO is expected to report earnings on Nov 17, 2022.

Industries' Descriptions

@Biotechnology (+3.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CELZ with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CELZ($5.89M) has a higher market cap than CYTO($1.76M). CELZ YTD gains are higher at: 19.916 vs. CYTO (-93.520). CELZ has higher annual earnings (EBITDA): -9.93M vs. CYTO (-22.48M). CELZ has more cash in the bank: 12M vs. CYTO (49.6K). CELZ has less debt than CYTO: CELZ (2.74M) vs CYTO (3.47M). CYTO has higher revenues than CELZ: CYTO (120K) vs CELZ (24.6K).
CELZCYTOCELZ / CYTO
Capitalization5.89M1.76M334%
EBITDA-9.93M-22.48M44%
Gain YTD19.916-93.520-21%
P/E Ratio2.66N/A-
Revenue24.6K120K21%
Total Cash12M49.6K24,194%
Total Debt2.74M3.47M79%
FUNDAMENTALS RATINGS
CELZ vs CYTO: Fundamental Ratings
CELZ
CYTO
OUTLOOK RATING
1..100
526
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5739
P/E GROWTH RATING
1..100
57100
SEASONALITY SCORE
1..100
n/a20

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTO's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for CELZ (65) in the null industry. This means that CYTO’s stock grew somewhat faster than CELZ’s over the last 12 months.

CYTO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CELZ (100) in the null industry. This means that CYTO’s stock grew similarly to CELZ’s over the last 12 months.

CELZ's SMR Rating (97) in the null industry is in the same range as CYTO (100) in the Biotechnology industry. This means that CELZ’s stock grew similarly to CYTO’s over the last 12 months.

CYTO's Price Growth Rating (39) in the Biotechnology industry is in the same range as CELZ (57) in the null industry. This means that CYTO’s stock grew similarly to CELZ’s over the last 12 months.

CELZ's P/E Growth Rating (57) in the null industry is somewhat better than the same rating for CYTO (100) in the Biotechnology industry. This means that CELZ’s stock grew somewhat faster than CYTO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELZCYTO
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GCT11.802.08
+21.40%
GigaCloud Technology
NBTB37.121.59
+4.49%
NBT Bancorp
GNLN0.580.01
+1.77%
Greenlane Holdings
ARMK28.290.28
+1.00%
ARAMARK
BPT3.540.01
+0.28%
BP Prudhoe Bay Royalty Trust

CELZ and

Correlation & Price change

A.I.dvisor tells us that CELZ and GNPX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELZ and GNPX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELZ
1D Price
Change %
CELZ100%
+2.70%
GNPX - CELZ
28%
Poorly correlated
-1.03%
AVRO - CELZ
25%
Poorly correlated
-2.27%
MIRO - CELZ
25%
Poorly correlated
-0.44%
TCON - CELZ
23%
Poorly correlated
-0.24%
CYTO - CELZ
23%
Poorly correlated
-19.66%
More